newsfilter
← Earnings
Earnings Releases·

Vera Therapeutics — Third Quarter 2026 Earnings Summary

  • Reported net product revenue of $10.3 million for Q3 2026 versus $0 in the prior-year period; net loss widened to $93.7 million ($1.30/share) from $80.3 million ($1.26/share) year-over-year.
  • R&D expenses decreased to $41.3 million due to capitalization of TRUTAKNA manufacturing costs, while SG&A expenses rose to $61.4 million reflecting commercial launch investments.
  • Company holds $384.0 million in cash and marketable securities as of September 30, 2026, with long-term debt increasing to $75.4 million.
  • Submitted sBLA for full TRUTAKNA approval on November 3, 2026, with potential full approval expected mid-2027 and EMA submission planned for Q1 2027.
  • TRUTAKNA launched with accelerated FDA approval on July 7, 2026, generating approximately 700 Patient Start Forms to date.
Company
VERA THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology